

## Akorn declares bankruptcy - Recalls all drug products

- On April 26, 2023, <u>Akorn announced</u> a voluntary consumer-level recall of multiple drug products as a result of the company declaring bankruptcy in February 2023 and ceasing all operations. The recall involves over 70 drugs, the majority of which are generics.
- The affected products are listed <u>here</u>. The products were distributed nationwide to wholesalers, retailers, manufacturers, medical facilities, repackagers and to consumers.
- The reason for the recall is because Akorn has discontinued any quality activities related to these drugs and will not be able to support or guarantee that these drugs will meet all intended specifications through their labeled shelf life.
  - The discontinuation of the quality program would result in the company's inability to assure that products meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess which render the products adulterated.
  - Per Akorn, while specific risks to patients, from use of these adulterated products, cannot always be identified or assessed, it is also not possible to rule out patient risks resulting from the use of such products.
  - To date Akorn has not received any reports of adverse events related to this recall.
- Contact Akorn at 1-800-932-5676 for questions regarding this recall.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.